$SGRY Balance Sheet | Understand Stock

$SGRY

$23.36 +$0.00 (0.0%) After hours

$SGRY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable
Inventories
Prepaid expenses
Other current assets
Total current assets
Property and equipment, net of accumulated depreciation of $718.0 and $651.2, respectively
Intangible assets, net
Goodwill
Goodwill and other intangible assets, net
Investments in and advances to affiliates
Right-of-use operating lease assets
Long-term deferred tax assets
Other long-term assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued payroll and benefits
Medicare accelerated payments and deferred governmental grants
Other current liabilities
Current maturities of long-term debt
Total current liabilities

Long-term debt, less current maturities
Right-of-use operating lease liabilities
Long-term deferred tax liabilities
Other long-term liabilities
Non-controlling interests—redeemable
Redeemable preferred stock - Series A; shares authorized - 310,000; shares issued or outstanding - none and 310,000, respectively; redemption value - none and $434.5, respectively
Stockholders' equity:
Preferred stock, $0.01 par value; shares authorized - 20,310,000; shares issued or outstanding - none
Common stock, $0.01 par value; shares authorized - 300,000,000; shares issued and outstanding - 130,886,397 and 129,321,144, respectively
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained deficit
Total Surgery Partners, Inc. stockholders' equity
Non-controlling interests—non-redeemable
Total stockholders' equity
Total liabilities and stockholders' equity

Comments